Stimulus Bill Creates Opportunities in Healthcare IT ::

March 11, 2009

The American Recovery and Reinvestment Act of 2009, signed by President Obama in February, allots $19.2B to Healthcare Information Technology, much of which will go toward a widespread transition to Electronic Health Records (EHRs).
 
The Revere Hierarchy enables users to rapidly identify specific sectors and companies most likely to be called upon to execute this transition. Two such sectors are:
 
Technology > Software > Industry-Specific > Healthcare/Pharma > Business Management/Information Systems (85 companies)
 
Technology > Information Technology (IT) Services > Enterprise and Technology Consulting > Industry-Specific IT Services > Healthcare (37 companies)
 
Through Revere Relationships , investors can further narrow down companies in this space to 34 that list the U.S. Government as a customer. Some examples include HLTH Corporation (Nasdaq: HLTH), Perot Systems Corporation (NYSE: PER), and Computer Sciences Corporation (NYSE: CSC).
 
For more information or assistance with identifying additional Healthcare IT investment opportunities, please don’t hesitate to contact our Research, Sales, and Customer Support Teams.
 
Sincerely,
 
The Revere Research Team
 
CONTACTS
Research: research@reveredata.com
Sales: sales@reveredata.com
Customer Support: support@reveredata.com


DISCLAIMER
Revere Data, LLC is an independent provider of investment research and information and does not offer investment advice. Any mention of a specific company is not a recommendation to buy or sell a security of that company. Revere Data, LLC permits its analysts and members of their immediate families to invest and trade in the securities of the companies in the industry and industries covered by Revere Data, LLC. Though Revere Data, LLC is not required to be a registered investment advisor under the Investment Advisor Act of 1940 or as an investment advisor with any state, Revere Data, LLC voluntarily applies relevant and pertinent rules and procedures adopted by the NYSE and NASD as may be approved from time to time by the SEC relating to the issues of analyst independence and objectivity.